Cao, Yunlong http://orcid.org/0000-0001-5918-1078
Wang, Jing http://orcid.org/0000-0002-9084-9985
Jian, Fanchong http://orcid.org/0000-0001-8703-3507
Xiao, Tianhe
Song, Weiliang
Yisimayi, Ayijiang
Huang, Weijin http://orcid.org/0000-0002-4246-8889
Li, Qianqian
Wang, Peng
An, Ran
Wang, Jing
Wang, Yao
Niu, Xiao
Yang, Sijie
Liang, Hui
Sun, Haiyan
Li, Tao
Yu, Yuanling
Cui, Qianqian
Liu, Shuo
Yang, Xiaodong
Du, Shuo http://orcid.org/0000-0003-0936-0785
Zhang, Zhiying http://orcid.org/0000-0002-5690-9796
Hao, Xiaohua
Shao, Fei
Jin, Ronghua
Wang, Xiangxi
Xiao, Junyu http://orcid.org/0000-0003-1822-1701
Wang, Youchun http://orcid.org/0000-0001-9769-5141
Xie, Xiaoliang Sunney http://orcid.org/0000-0001-9281-5239
Article History
Received: 7 December 2021
Accepted: 23 December 2021
First Online: 23 December 2021
Competing interests
: X.S.X. and Y.C. are listed as inventors on a patent related to BD series antibodies and DXP-604 (PCT/CN2021/093305) under Peking University. X.S.X. and Y.C. are founders of Singlomics Biopharmaceuticals. The remaining authors declare no competing interests.